Traws Pharma, Inc. cotiza a 0.40 USD y tiene una capitalización bursátil de $6M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor …
| Periodo | 2026-05 | 2026-04 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.52 | $-0.71 | $-0.34 | — |
| Estimado | $-0.56 | $-1.91 | $-9.16 | $-8.75 |
| Sorpresa | +7.1% | +62.8% | +96.3% | — |
| Métrica | TRAW | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -640.7% | -38.6% | -602.1% |
| Net Margin | 328.7% | -33.6% | +362.2% |
| FCF Margin | -744.4% | -13.9% | -730.6% |
| ROE | — | -40.4% | — |
| ROA | 86.4% | -32.0% | +118.4% |
| Current Ratio | 0.72 | 2.84 | -2.12 |
| Debt / Equity | — | 0.28 | — |